{"nctId":"NCT01374490","briefTitle":"Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea","startDateStruct":{"date":"2011-06-07","type":"ACTUAL"},"conditions":["HIV Enteropathy","Diarrhea With HIV"],"count":250,"armGroups":[{"label":"Crofelemer","type":"EXPERIMENTAL","interventionNames":["Drug: Crofelemer"]}],"interventions":[{"name":"Crofelemer","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female ≥ 18 years old\n* History of HIV-1 infection\n* On an antiretroviral therapeutic regimen for treatment of HIV-1 disease and associated conditions (including prophylactic antibiotics for Pneumocystis jirovecii or infection) for at least 4 weeks prior to screening\n* Self-reported presence of diarrhea necessitating ADM use for at least 4 weeks\n\nExclusion Criteria:\n\n* CD4 counts \\< 100 cells/mm3\n* Oral temperature greater than 38.0° C, or unintentional weight loss of 5.0 kg or greater during the prior 2 months\n* Bright red blood per rectum judged not to be of an anal (e.g., hemorrhoid, fissure) origin\n* Immediate need for GI surgery or intervention for active GI bleeding, pancreatitis, peritonitis, intestinal obstruction, or intra-abdominal abscess","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs).","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":250},"commonTop":["Upper respiratory tract infection","Parasitic infection intestinal","Giardiasis","Bronchitis","Constipation"]}}}